Orchid Chemicals & Pharmaceuticals Limited

Orchid Research Laboratories Limited

Virendra Kachhadia

Sriram K Rajagopal

Ravikumar Tadiparthi

Gaddam Om Reddy

Venkatesan Parameswaran

Sridharan Rajagopal

Uma Ramachandran

Ganapavarapu Veera Raghava Sharma

Sukunath Narayanan

Venkatesan Janarthanam

Maruthikumar Narayanam

Sathya Narayana Thara

Sathyanarayana Gadde

Durairaj Peter Bhakiaraj

Akella Satya Surya Visweswara Srinivas

Abdul Raheem Keeri

Thanasekaran Ponpandian

Gopalan Balasubramanian

Shridhar Narayanan

Sanjeev Saxena

Sappanimuthu Thirunavukkarasu

Urkalan Kaveri Balan

Lolaknath Santosh Vishwakarma

Narayanan Surendran

Narayana Swamy Punthalir

Rama Swamy Velmurugan

Kilambi Narsimhan

Visweswara Akella Satya Surya Srinivas

Om Reddy Gaddam

Kilambi Narasimhan

Thirunavukkarasu Sappanimuthu

Prabhu Daivasigamani

Rajendran Praveen

Karnambaram Anandhan

Punthalir Narayanaswamy

Balaji Ramachandran

Kamaraj Mani

Praveen Rajendran

Suresh Rathinasamy

Umamaheswari Mani

Ganapavarapu Veera Sharma

Visweswara Akella Srinivas

Provided herein are novel, stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds can inhibit HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, etc. 

Histone deacetylase inhibitors

Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I). 

Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases. 

Pyrimidine compounds and their uses

The present invention relates to novel stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel stilbene like compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I) as described above. 

Stilbene like compounds as novel HDAC inhibitors

Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell-damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors, and useful for treating PDE4 mediated diseases. 

Heterocycles

Growing community of inventors

Chennai, India

Virendra Kachhadia